Opinion

Video

Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

Experts give an overview of the ASCO 2024 data.

Video content above is prompted by the following question:

The phase 2 CORE-001 trial investigated a new treatment combination of intravesical cretostimogene grenadenorepvec with pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC. Before we review the trial background and results presented at the ASCO 2024 Annual Meeting, can you introduce cretostimogene and describe its mechanism of action?

Related Videos
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
© 2025 MJH Life Sciences

All rights reserved.